Mosunetuzumab Expands Promise in Mantle Cell and Marginal Zone Lymphoma: Phase II Results
Mosunetuzumab showed early promise for improving outcomes in two key lymphoma subtypes with 88% response rates in MCL.
Non-Hodgkin Lymphoma
Latest Post
Circulating Tumor DNA Outperforms PET Imaging for Minimal Residual Disease Detection in Large B-Cell Lymphoma
ctDNA detection after LBCL therapy predicts 97% vs 29% progression-free survival, superior to PET scans...
POLARGO Trial: Polatuzumab Vedotin Improves Survival in Relapsed/Refractory DLBCL
40% reduction in death risk with Pola-R-GemOx vs R-GemOx alone in relapsed/refractory DLBCL (HR 0.60,...
